Targeting protein prenylation in progeria.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 23390246.
- Also identified by DOI 10.1126/scitranslmed.3005229 and PMC identifier 3725554.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A clinical trial of a protein farnesyltransferase inhibitor (lonafarnib) for the treatment of Hutchinson-Gilford progeria syndrome (HGPS) was recently completed. Here, we discuss the mutation that causes HGPS, the rationale for inhibiting protein farnesyltransferase, the potential limitations of this therapeutic approach, and new potential strategies for treating the disease.
Medical subject headings
- Progeria
- Protein Prenylation